For the roughly 37 million Americans with diabetes, the standard of care is a daily ritual of needles and vials. Managing blood sugar is a constant calculation of insulin doses, carbohydrate intake, and finger-prick tests, a burden that defines life with the disease. A needle-free alternative has been a long-sought goal in biotech, and for over a decade, Transdermal Specialties Global (TSG) has been working on one: a transdermal patch that uses ultrasound to deliver insulin through the skin [Drug Development & Delivery, 2016].
Founded by former NASA mission specialist Bruce K. Redding Jr., the company patented its U-Strip technology, which applies ultrasonic frequencies to temporarily expand pores in the skin, allowing large molecules like insulin to pass into the bloodstream [BioBuzz, undated] [Justia Patents Search, undated]. The vision was a five-day wearable patch, a significant leap from the multiple daily injections that are the current reality for many patients. The company even claimed production capacity for over one million patches per week at a plant in Charlotte, North Carolina, as of 2016 [Drug Development & Delivery, 2016]. Yet, the path from lab to pharmacy shelf is notoriously long and expensive, a reality that appears to have caught up with the venture. In May 2021, Transdermal Specialties Global filed for bankruptcy [PacerMonitor, 2021].
The technical wedge and its promise
The core scientific challenge TSG aimed to solve is the skin's natural barrier. Traditional transdermal patches, like those for nicotine or hormones, can only deliver very small molecules. Insulin is a large, complex protein, and getting it through the skin without a needle has been a major hurdle. The U-Strip's proposed mechanism of action was its wedge. By using controlled ultrasound, the company claimed it could deliver not just insulin but a pipeline of over 175 other compounds, including drugs for central nervous system disorders [Drug Development & Delivery, 2016]. For patients, the appeal is visceral: reduced pain, no needle anxiety, and potentially improved adherence to therapy. For a healthcare system managing a chronic condition, a reliable, user-friendly delivery method could translate to better long-term outcomes and lower complication rates.
The long road to a closed-loop system
TSG's ambitions extended beyond a simple patch. The company's website outlined a roadmap toward a closed-loop system, integrating continuous glucose monitoring with automated insulin delivery via the patch, targeted for clinical trials in 2026 [company website, undated]. This represents the holy grail of diabetes management: an artificial pancreas. Achieving this would require not just proving the delivery technology, but seamlessly integrating sensing, algorithms, and actuation in a single, wearable, regulatory-approved device. It's a multibillion-dollar problem being pursued by much larger, well-funded players. The company's stated progress included forming a subsidiary, Transdermal Global, to advance Phase III trials for its insulin patch, though detailed, peer-reviewed results from those trials are not publicly available [Drug Development & Delivery, 2016].
A founder's patents and a company's silence
The story of TSG is inextricably linked to its founder, Bruce K. Redding Jr. A former NASA mission specialist, Redding is listed as an inventor on more than 60 patents, a track record that lends technical credibility to the venture's core IP [BioBuzz, undated] [Justia Patents Search, undated]. The company relocated its headquarters to Frederick, Maryland, in October 2020, a move framed as a commitment to its biotech hub [PRWeb, October 2020]. However, the signals since then have been sparse. The bankruptcy filing seven months later is the most definitive public marker. No venture funding rounds, strategic partnerships, or major pharmaceutical licensing deals are documented in the available record. Third-party analysts currently label the company as not active [Tracxn, 2025].
| Aspect | Status (Per Public Record) |
|---|---|
| Core Technology | Patented U-Strip for ultrasonic transdermal delivery [Drug Development & Delivery, 2016] |
| Lead Indication | Insulin delivery for Type 1 & 2 Diabetes |
| Key Milestone (Claimed) | Phase III trial preparation, >1M patch/week production capacity (2016) [Drug Development & Delivery, 2016] |
| Recent Corporate Status | Filed for Chapter 11 bankruptcy (May 2021) [PacerMonitor, 2021] |
| Founder Background | Bruce K. Redding Jr., former NASA specialist with 60+ patents [BioBuzz, undated] |
The risks beyond the science
The most immediate challenge for any revival of the TSG concept is financial. Developing a novel drug delivery system through clinical trials and the FDA regulatory process requires deep, patient capital, often in the hundreds of millions of dollars. The bankruptcy suggests that capital runway was exhausted. Furthermore, the competitive landscape for non-invasive insulin delivery has grown, with other technologies like oral insulin capsules and inhaled insulin products also in various stages of development. Even if the U-Strip technology is sound, it must now prove not just efficacy and safety, but also significant advantages in cost, convenience, and reliability over both existing injections and these emerging alternatives.
For the target patient population,individuals with Type 1 and insulin-requiring Type 2 diabetes,the standard of care today remains a mix of multiple daily injections with syringes or insulin pens, and insulin pumps. These methods are effective but impose a significant burden. The promise of a painless patch that could automate delivery represents a profound quality-of-life improvement. The story of Transdermal Specialties Global underscores a common, difficult truth in health tech: a compelling patient need and an elegant technical solution are necessary, but rarely sufficient. They must be matched with resilient financing, rigorous clinical validation, and a viable path through a complex regulatory and commercial gauntlet. The company's patents and prototype work remain a testament to the ambition; their future application now depends on a path out of financial restructuring.
Sources
- [Drug Development & Delivery, 2016] Executive Interview: Transdermal Specialties - A New Dimension in Transdermal Drug Delivery | https://drug-dev.com/executive-interview-transdermal-specialties-a-new-dimension-in-transdermal-drug-delivery/
- [BioBuzz, undated] In Conversation: Bruce K. Redding Jr. | https://biobuzz.io/in-conversation-bruce-k-redding-jr-ceo-of-transdermal-specialties-global/
- [Justia Patents Search, undated] Bruce Redding Inventions, Patents and Patent Applications | https://patents.justia.com/inventor/bruce-redding
- [PacerMonitor, 2021] Transdermal Specialties Global, Inc. Bankruptcy | https://www.pacermonitor.com/public/case/40302714/Transdermal_Specialties_Global,_Inc
- [PRWeb, October 2020] Transdermal Specialties Global (TSG) announces relocation to Frederick, MD | https://www.prweb.com/releases/Transdermal_Specialties_Global_TSG_announces_that_it_has_relocated_to_Frederick_MD/prweb17447086.htm
- [company website, undated] Leadership page referencing closed-loop system | https://u-strip.com/leadership/
- [Tracxn, 2025] Transdermal Specialties - 2025 Company Profile & Competitors | https://tracxn.com/d/companies/transdermal-specialties/__J_8ZVX4PfgZKdZqdtngrC6u4wfBFVHJr1BYyMltp-8M